Digital First Scientific Communications – Generative AI: Changing the future of MedComms
In this podcast, we interview Matt Lewis, Chief AI Officer at Inizio Medical, a well-regarded expert in data analytics and augmented intelligence.
In this podcast, we interview Matt Lewis, Chief AI Officer at Inizio Medical, a well-regarded expert in data analytics and augmented intelligence.
The session focuses on results from first hand experiences in Chat GPT and other Large Language Models (LLMs).
ChatGPT is disrupting content creation, from term papers to journal articles to online information mills and more. This webinar gathers three thought leaders at the cutting edge of this issue to vision how ChatGPT may augment or, at times, undermine the practice of Medical Affairs in areas such as Medical Information, Omnichannel engagement and more.
This article provides top-level framework and broad conceptual categories for understanding digital structures within Medical Affairs and biopharmaceutical/MedTech organizations, helping leaders to make organizational decisions to drive their digital strategy with intention and purpose.
With a multibillion dollar investment from Microsoft and already 4 authorship credits on PubMed, ChatGPT is poised to disrupt Medical Affairs.
MAPS speaks with Tim Mikhelashvili, CEO and Co-Founder of Amedea Pharma, and the winners of his Medical Affairs Olympics Competition, the CEOs of Discreedly and Inphronesis.
In today’s episode, we’re talking with Joseph Zabinski, PhD, Senior Director, AI & Personalized Medicine at OM1 about Artificial Intelligence — specifically about how AI can accelerate diagnosis and treatment.
This Webinar aims to achieve awareness on challenges and solutions when listening to, and interacting with, Digital Opinion Leaders.
In this our second episode this season, we’ll be discussing open access in medical publishing from the biopharma perspective.
In this webinar, experts will lay the foundation of what conversational AI is, best and emerging practices, provide use cases, and discuss regulatory and legal considerations.